Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-free mitochondrial DNA and microRNA-137 for early diagnosis of preeclampsia.

Frontiers in cardiovascular medicine·2026
Same author

Utility of Right Ventricular Mass Ratios in Recipients With Pulmonary Hypertension: A United Network for Organ-Sharing Database Analysis.

Clinical transplantation·2026
Same author

Impact of 2018 Donor Heart Allocation Policy Change on Patients on Biventricular Support: A UNOS Database Analysis.

Artificial organs·2025
Same author

Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change.

Artificial organs·2025
Same author

Veno-pulmonary extracorporeal membrane oxygenation for concomitant right ventricular and respiratory support: A systematic review of utilization patterns and outcomes.

Perfusion·2025
Same author

Ideal Body Weight Ratio for Donor-to-Recipient Size Matching in Heart Transplantation.

Clinical transplantation·2025
Same journal

Effectiveness of Nurse-Led Telemonitoring Versus Usual Care on Readmission and Mortality Rates in Patients With Chronic Heart Failure: A Meta-Analysis.

The Journal of cardiovascular nursing·2026
Same journal

Contemporary Lipid Guidelines: Key Updates and Implications for Cardiovascular Nurses.

The Journal of cardiovascular nursing·2026
Same journal

The Interplay Between Physical Symptoms, Benefit Finding, Patient Activation, Social Support, Family Function, and Hope in Patients With Heart Failure: A Network Analysis.

The Journal of cardiovascular nursing·2026
Same journal

Self-Care, Treatment Adherence, and Frailty in Older Adults With Hypertension: A Descriptive Correlational Study.

The Journal of cardiovascular nursing·2026
Same journal

Predictors of Prolonged Intensive Care Unit Stay After Heart Valve Surgery: A Case-Control Study.

The Journal of cardiovascular nursing·2026
Same journal

Characteristics and Care Practices in People Hospitalized for Heart Failure With Coexisting Diabetes: A Single-Center Retrospective Observational Study.

The Journal of cardiovascular nursing·2026
See all related articles

Related Experiment Videos

Aldosterone antagonists in heart failure.

Susan E Miller1, René J Alvarez

  • 1Susan E. Miller, DNP, RN, PCCN Assistant Professor, School of Nursing, Acute and Tertiary Care Department, University of Pittsburgh, Pennsylvania. René J. Alvarez Jr, MD, FACC, FAHA Professor of Medicine, Medical Director, Advanced Heart Failure/Cardiac Transplantation, Vice Chief, Section of Cardiology, and Assistant Dean for Minority Faculty Affairs, School of Medicine, Temple University, Philadelphia, Pennsylvania.

The Journal of Cardiovascular Nursing
|September 25, 2012
PubMed
Summary
This summary is machine-generated.

Aldosterone antagonists are life-saving medications for systolic heart failure, reducing mortality and hospitalizations in severe cases. Further research is exploring their use in milder heart failure stages.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic systolic heart failure presents a growing health burden.
  • Evolving treatments incorporate pathophysiology-based approaches, including aldosterone antagonists.

Purpose of the Study:

  • Review literature and guidelines on aldosterone antagonist use in systolic heart failure.
  • Address the detrimental cardiovascular effects of aldosterone, including ventricular remodeling and endothelial dysfunction.

Main Methods:

  • Literature review
  • Guideline analysis

Main Results:

  • Aldosterone antagonists decrease mortality in patients with New York Heart Association class III-IV heart failure.
  • These drugs reduce mortality and hospital readmissions in post-myocardial infarction heart failure patients.

Conclusions:

  • Aldosterone antagonists are crucial for neurohormonal blockade in systolic heart failure treatment.
  • Potential expansion of aldosterone antagonist use to less severe heart failure forms is under investigation.
  • Hyperkalemia is a key complication, manageable through careful patient selection and monitoring.